The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy

The adequate management of cancer chemotherapy side effects continues to be a challenging problem. There is considerable variability in the side effects experienced by different patients to the same chemotherapeutic drugs. Clinical observations and previous findings of neuropathways between the vestibular system and vomiting center prompted this case‐control study of whether susceptibility to motion sickness is a determinant of the type and magnitude of the side effects resulting from cancer chemotherapy. Eighty‐three of 486 (17%) consecutive patients who were receiving chemotherapeutic drugs as their only treatment for histologically confirmed cancer reported previous motion sickness. Seventy‐seven of these study patients were matched to cancer patient controls without previous motion sickness by sex, age, type and dose of chemotherapeutic drug received, and antiemetic medication. Study patients reported significantly greater nausea and vomiting (P < 0.05), significantly more side effects (P < 0.05), and a pattern of more frequent, severe, and longer‐lasting nausea and vomiting than controls. Susceptibility to motion sickness appears to be a determinant of the side effects of cancer chemotherapy that may prove useful as a clinical marker of those patients who may require more intensive side effect management.

[1]  G. Keinan,et al.  Biographical, physiological, and personality variables as predictors of performance under sickness-inducing motion. , 1981 .

[2]  M. Morrow,et al.  Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma? , 1984, Cancer.

[3]  G. Morrow.  Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. , 1984, Cancer.

[4]  J P Landolt,et al.  Motion sickness caused by rotations about Earth-horizontal and Earth-vertical axes. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.

[5]  J. Laszlo,et al.  Emesis as a critical problem in chemotherapy. , 1981, The New England journal of medicine.

[6]  T. Burish,et al.  Effectiveness of relaxation training in reducing the aversiveness of chemotherapy in the treatment of cancer , 1979 .

[7]  S. Frytak,et al.  Management of nausea and vomiting in the cancer patient. , 1981, JAMA.

[8]  H. L. Borison,et al.  Physiology and pharmacology of vomiting. , 1953, Pharmacological reviews.

[9]  G. Morrow,et al.  Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. , 1982, The New England journal of medicine.

[10]  R. Gralla,et al.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. , 1981, The New England journal of medicine.

[11]  P. Silberfarb,et al.  Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. , 1980, The American journal of psychiatry.

[12]  G. Morrow.  Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. , 1982, Journal of the National Cancer Institute.

[13]  M. Hawken,et al.  Unit activity from cat area postrema influenced by drugs , 1975, Brain Research.

[14]  H. L. Borison,et al.  Area postrema: chemoreceptor trigger zone for vomiting--is that all? , 1974, Life sciences.

[15]  D. Longo,et al.  The control of chemotherapy-induced emesis. , 1981, Annals of internal medicine.

[16]  M. Andrykowski,et al.  Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. , 1982, Journal of consulting and clinical psychology.

[17]  M. Treisman.  Motion sickness: an evolutionary hypothesis. , 1977, Science.

[18]  J. Bennett,et al.  Home dialysis does cost less than outpatient dialysis. , 1982 .

[19]  Whitehead Vm.  Letter: Cancer treatment needs better antiemetics. , 1975 .

[20]  M. Zelen,et al.  Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. , 1980, The New England journal of medicine.